et al. Effect of a web-based guided self-help intervention for prevention of major depression in adults with subthreshold depression: a randomized clinical trial. JAMA.
Indicated prevention has been suggested to be more "efficient" than selective prevention [20] .
51
"Efficiency" is here defined in terms of "impact", that is the number of cases that would be 52 prevented if the targeted risk indicator were fully blocked in the population and "effort" participants can work at their own pace and go through materials as often as they want, and
74
(e) elimination of travel time and costs for both participants and clinicians. Finally (f), web- knowledge, no study has yet investigated the (cost-) effectiveness of an indicated guided self-84 help web-based preventive intervention on the onset of diagnosed major depressive disorders.
85
Objective and research questions 86 The aim of this study is to evaluate whether a newly developed indicated guided self-help 
Methods

94
Design 95
A two-armed randomised controlled trial (RCT) will be conducted to compare GET.ON
96
Mood Enhancer Prevention with a psychoeducation-only control condition. Measurements 97 will be taken at baseline, post-treatment (6 weeks), 6, and 12 months follow-up (after 
103
Inclusion and exclusion criteria 104
We will include adults (a) age 18 and above who (b) suffer from subthreshold depression They do not need to be referred by their GP or other mental health care specialist.
123
Assessment of eligibility and randomisation 124
People who apply online for study participation receive an information letter via e-mail with 125 detailed information about the study procedures. They will be informed that they can 126 withdraw from the intervention and/or study at any time without any negative consequences. baseline assessment and returned the informed consent form via post or e-mail will enter the 136 study and will be randomly allocated to study conditions. Randomisation will take place at an 137 individual level. Block randomisation will be used to ensure equity of ample sizes across 138 study conditions. Random blocks will consist of two allocations each. The allocation will be 139 done by an independent researcher not otherwise involved in the study using an automated 140 computer-generated random numbers table.
141
Blinding 142
The research staff conducting the semi-structured clinical interviews at 6-and 12-months 143 follow-up will be blinded to the condition the participants are assigned to. These include: (a) 144 an explanation to the participants why it is important not to inform the interviewer about the to the latter, the interviewer will be asked to guess each participant's randomisation status and 150 these guesses will be compared with the actual status. Cohen's kappa will be computed to 151 clarify whether hit rates differ from what can be expected from chance. In case of evidence 152 for blinding break down, the interviewer will be changed to the second outcome interview. 
212
Sample size calculation 213
We assume an absolute risk reduction of at least 10% for the incidence of major depressive of 10% between the groups using log rank survival analyses (calculated using PASS 12).
220
Outcome measurements 221
For an overview of assessment at baseline, post-treatment, 6-and 12-month follow-up see 222   Table 1 .
223
Primary outcome
224
The primary outcome is time to onset of MDD within a 12-months follow-up period. Major agreement between face-to-face and telephone SCID interviews as indicated by the kappa 229 coefficient is considered to be excellent [52] . Time to onset of MDD will be assessed using 230 life charts. Life events are recalled by using a calendar method after which the presence of 231 depressive symptoms at each month during the follow-up period is determined. SCIDs will be 232 conducted by trained psychologists who are blind to treatment condition. The interviews will 233 be recorded to examine inter-rater reliability. Disagreement shall be solved by discussion and 234 the agreed rating will be used for analysis. If this is not possible, the assessment will be rated 235 by an experienced psychotherapist (gold standard) and this rating will be used for analysis.
237
Secondary outcomes 238
Self-report data will be collected using a secured online-based assessment system (AES, 256-239 bit encrypted).
241
Depressive symptomatology 242 The depressive symptom level will be assessed with the German version of the Center for 
Quality of life 252
Health-related quality of life will be assessed with two multidimensional generic measures, 
Key economic outcomes
335
Clinical endpoints
336
In the cost-effectiveness analyses, the main outcome will be depression-free years gained.
337
Depression-free years will be assessed by calculating the difference in follow-up lengths and 338 the duration of any major depressive episode (i. e. period of time in weeks that a person met 339 DSM-IV criteria). In the cost-utility analysis, quality-adjusted life years (QALYs) will be the 340 clinical endpoint. QALYs will be obtained from the EQ-5D (EuroQol) and SF-6D (SF-12v1).
341
The EuroQol will be used because it is a widely applied quality of life instrument and its which is a self-report questionnaire [77] . Indirect non-medical cost stemming from production 358 losses due to absenteeism and presenteeism will be assessed with specific modules of the TiC- 
Clinical efficacy
365
The study will be conducted in agreement with the CONSORT statement. We will calculate 366 the Kaplan-Meier estimates of the survival function for the intervention and control group.
367
We will plot the Kaplan-Meier curves with the corresponding 95% confidence intervals. We 368 will analyse differences in survival times between intervention and control group using the 369 log-rank test. The log-rank test, however, does not allow other explanatory variables to be 370 taken into account. We will additionally perform a Cox proportional hazard regression 371 analysis to model time until onset of major depressive disorder while simultaneously 372 adjusting for baseline depressive symptom severity. We will use person-time based Poisson 373 regression to obtain incidence rate ratios (IRRs) in addition to hazards rates obtained from
374
Cox regression. Time to onset will be the dependent variable in the survival analyses.
375
Analyses will be done based on the intention-to-treat (ITT) principle. In addition, per-protocol 376 analyses will be performed. For participants who are lost from the trial, available 377 measurements will be used and then censored at the time of their last observation. Participants 378 who miss the assessment at 6-months follow-up, but are then assessed at 12-months follow-379 up, will be asked about their current and past symptoms according to SCID diagnostic criteria 380 since the diagnostic interview at baseline. This will enable us to assess the time to onset of a 381 depressive episode and thus to censoring. One-sided tests will be used for testing 382 unidirectional and two-sided tests for testing bidirectional hypotheses. For all analyses 383 statistical significance will be set at p < .05. We will calculate the number needed-to-be- In secondary analyses, hierarchical linear modelling will be used to assess differences in 387 secondary outcomes, such as depressive symptom severity, anxiety, and quality of life. We 388 will also explore the proportion of major depressive episodes in the intervention and control 
Economic analyses
394
It will be checked whether baseline differences exist between the intervention and control 395 group. If necessary, statistical techniques will be used to correct for baseline differences [80] .
396
In the cost-effectiveness analyses, the incremental cost-effectiveness ratio (ICER) will be 397 stated as costs per depression-free years gained, whereas the ICER in the cost-utility analyses 398 will represent the costs per quality-adjusted life year (QALY) gained. Bootstrapping will be 399 used to test the robustness of the ICERs and quantify the uncertainty around the ratios that 400 will be graphically represented on a cost-effectiveness plane. The bootstrapped ICERs will 401 also be shown in a cost-effective acceptability curve disclosing the probability that GET.ON
402
Mood Enhancer Prevention is cost-effective for a wide range of willingness-to-pay ceilings
403
[81]. To test the robustness of the base-case findings, a multi-way sensitivity analysis will be 404 done. An incremental net benefit regression analysis will be performed to ascertain which 405 sub-groups benefit more from the intervention in terms of superior cost-effectiveness. 
